Amirmohsen Jalaeefar1, Ashraf Moini2,3,4, Bita Eslami2, Sadaf Alipour2,5, Mohammad Shirkhoda1, Arvin Aryan6, Habibollah Mahmoodzadeh1,2, Ramesh Omranipour1,2. 1. Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. 2. Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. 5. Department of Surgery, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Radiology, Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Anti-Müllerian hormone (AMH) is a known sensitive biomarker for fertility and ovarian reserve. The results of in vivo and human studies showed inconsistency with respect to the relation between AMH and breast cancer. OBJECTIVE: To compare the AMH level of young Iranian women with early breast cancer who have not received any treatment compared to that of healthy women. MATERIALS AND METHODS: In this case-control study, 58 breast cancer cases were recruited from the breast oncology clinic of two university hospitals. They were diagnosed with an in situ or invasive breast cancer before any anticancer treatment between August 2018 and April 2019. Healthy controls (n = 58) were selected from women referred to a gynecologic outpatient clinic without any symptoms of cancer or infertility. AMH was measured by the AMH enzyme-linked immunosorbent assay kits in one laboratory. RESULTS: Final analysis showed that the AMH means of case and control were not statistically significant (3.36 ± 2.95 vs 3.13 ± 1.79). However, the lower and higher AMH level categories are more prevalent in breast cancer compared to the control. Pearson's correlation test showed that the AMH level was negatively correlated with age (r = -0.44, p < 0.001). The results of logistic regression analysis considering confounding factors showed the positive association between breast cancer and lower (Odds Ratio [OR] = 5.98, p = 0.02) and higher quartile of AMH level (OR = 4.95, p = 0.01). CONCLUSION: Our results suggest that abnormal AMH level is more frequent in young breast cancer patients. Further investigation considering AMH determinants is required.
BACKGROUND: Anti-Müllerian hormone (AMH) is a known sensitive biomarker for fertility and ovarian reserve. The results of in vivo and human studies showed inconsistency with respect to the relation between AMH and breast cancer. OBJECTIVE: To compare the AMH level of young Iranian women with early breast cancer who have not received any treatment compared to that of healthy women. MATERIALS AND METHODS: In this case-control study, 58 breast cancer cases were recruited from the breast oncology clinic of two university hospitals. They were diagnosed with an in situ or invasive breast cancer before any anticancer treatment between August 2018 and April 2019. Healthy controls (n = 58) were selected from women referred to a gynecologic outpatient clinic without any symptoms of cancer or infertility. AMH was measured by the AMH enzyme-linked immunosorbent assay kits in one laboratory. RESULTS: Final analysis showed that the AMH means of case and control were not statistically significant (3.36 ± 2.95 vs 3.13 ± 1.79). However, the lower and higher AMH level categories are more prevalent in breast cancer compared to the control. Pearson's correlation test showed that the AMH level was negatively correlated with age (r = -0.44, p < 0.001). The results of logistic regression analysis considering confounding factors showed the positive association between breast cancer and lower (Odds Ratio [OR] = 5.98, p = 0.02) and higher quartile of AMH level (OR = 4.95, p = 0.01). CONCLUSION: Our results suggest that abnormal AMH level is more frequent in young breast cancer patients. Further investigation considering AMH determinants is required.
Authors: Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte Journal: Int J Cancer Date: 2018-02-08 Impact factor: 7.396
Authors: V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran Journal: Proc Natl Acad Sci U S A Date: 2005-02-22 Impact factor: 11.205
Authors: D L Segev; T U Ha; T T Tran; M Kenneally; P Harkin; M Jung; D T MacLaughlin; P K Donahoe; S Maheswaran Journal: J Biol Chem Date: 2000-09-15 Impact factor: 5.157
Authors: A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-03-09 Impact factor: 4.254